Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of XXXX .

@entity1 @entity308 @entity1674 @entity910 @entity914 @entity161 @entity1037 @entity1090
Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 @entity1 diagnosed with @entity161 or @entity914 . All initiated treatment with @entity1090 . Early response was defined as > or =20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on @entity1090 , whereas early non-responders (ENRs) were randomized (1 : 1) to continue on @entity1090 2-6 mg/day or switch to @entity1037 10-20 mg/day for 10 additional weeks. Compared with ENRs, @entity1090 ERs showed significantly greater reduction in PANSS total score (end point; p<001). Early response/non-response was highly predictive of subsequent clinical outcomes. Switching @entity1090 ENRs to @entity1037 at week 2 resulted in a small but significantly greater reduction in PANSS total score (end point; p=0.020) and in @entity308 (end point; p=0.004); the reduction in PANSS was greater among those who were still moderately ill at 2 weeks. Switching @entity1090 ENRs to @entity1037 also resulted in significantly greater increases in @entity1674 , a significantly greater decrease in prolactin, and significantly less treatment-emergent @entity910 . This is the first study to prospectively show that early response/non-response to an antipsychotic ( @entity1090 ) is a reliable clinical marker of subsequent clinical outcomes and that a 'switching' strategy based on this information may lead to greater clinical improvement than staying on a drug for a longer period in some @entity1 .
